By Chor-Ching Fan

In the life sciences industry, autonomous systems promise to accelerate everything from quality operations and laboratory workflows to manufacturing and regulatory processes. But they also raise an important question: How do you validate and govern software that doesn’t simply execute instructions, but makes decisions on its own? The answer begins with GAMP 5.

GAMP 5: A Lifecycle Approach to Quality

For more than a decade, GAMP 5 has served as the foundation for validating computerized systems across the pharmaceutical industry. Rather than prescribing rigid procedures, the framework encourages organizations to apply a risk-based approach that focuses on what ultimately matters: protecting patient safety, ensuring product quality, and maintaining data integrity. One of GAMP 5’s most enduring principles is that quality cannot be treated as a one-time exercise. Computerized systems should be designed, validated, operated, monitored, and retired through a managed lifecycle. Validation is not simply documentation produced before go-live. It is evidence that a system continues to perform as intended throughout its operational life.

That philosophy has proven highly effective for traditional software. Autonomous systems, however, introduce new dynamics that make continuous oversight even more important.

Autonomous Systems Change the Validation Conversation

Autonomous systems operate differently from validated software. While they should always remain within defined boundaries, they may make different decisions based on changing inputs, execute complex workflows without human intervention, or interact with multiple enterprise systems in ways that are difficult to evaluate through traditional validation alone. This evolution shifts an important question. Instead of asking, “Was the system validated before deployment?” organizations increasingly need to ask, “How do we know the system continues to operate within its validated state?” But this is not a departure from GAMP 5—it is an extension of its lifecycle philosophy.

Continuous Assurance, Not Periodic Validation

As AI becomes more deeply integrated into regulated operations, validation must become a continuous discipline rather than a milestone. Organizations need ongoing evidence that autonomous systems are behaving appropriately, that risks remain within acceptable limits, and that unexpected behavior can be identified before it impacts product quality or compliance. This requires operational visibility that extends well beyond traditional documentation. Continuous monitoring provides that visibility by creating an ongoing picture of how autonomous systems behave in production. Rather than relying solely on periodic reviews, organizations can observe system performance in real time, detect deviations as they emerge, and maintain objective evidence that systems remain under control. This approach aligns naturally with the broader direction of regulatory thinking, which increasingly emphasizes lifecycle management, risk management, and continuous assurance over static documentation.

Looking Beyond GAMP 5

Although GAMP 5 provides an essential framework, it is only one part of the quality landscape that life sciences organizations must navigate. Companies deploying autonomous systems must also satisfy requirements for electronic records, data integrity, software assurance, and emerging AI governance expectations.

Across these regulations and guidance documents, several common themes consistently emerge:

  • Transparency into how systems operate
  • Traceability of decisions and actions
  • Risk-based oversight throughout the system lifecycle
  • Evidence that systems remain in a state of control

These expectations become significantly easier to meet when they are supported by technology rather than manual processes.

The Platform Matters

Historically, compliance has often been layered onto software after it has been developed. Monitoring tools, audit logs, validation documents, and governance processes are assembled from multiple systems to demonstrate compliance during inspections. That approach becomes increasingly difficult as autonomous systems become more sophisticated. A more sustainable model is to build autonomous applications on platforms designed for continuous monitoring from the outset. When observability, governance, and policy enforcement are part of the underlying platform, organizations can demonstrate ongoing control instead of periodically reconstructing evidence after the fact. This doesn’t replace GAMP 5. It enables organizations to fulfill its lifecycle principles in an environment where software is becoming increasingly autonomous.

A New Era of Regulated Autonomy

The life sciences industry has always embraced innovation carefully, balancing new technology with rigorous quality expectations. Autonomous AI is no exception. GAMP 5 remains as relevant today as ever because its central message has never been about documentation but rather building quality into the entire lifecycle of computerized systems. As autonomous systems become part of everyday pharmaceutical operations, the organizations that succeed will be those that extend this lifecycle mindset beyond validation and into continuous monitoring. Compliance will increasingly depend not only on proving that a system was validated, but on continuously demonstrating that it remains trustworthy, governed, and operating within its intended boundaries. That shift represents more than a new compliance strategy. It is the foundation for deploying autonomous systems responsibly in regulated environments.

Related Posts: